Atazanavir: New option for treatment of HIV infection

Clinical Infectious Diseases

Volumn 38, Issue 11, 2004, Pages 1599-1604

  Havlir, Diane V ^a   O'Marro, Steven D ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Springfield Clinic   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BILIRUBIN; CHOLESTEROL; CLARITHROMYCIN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VIROLOGY; VIRUS MUTATION;

DRUG RESISTANCE; HIV INFECTIONS; HUMANS; OLIGOPEPTIDES; PYRIDINES;

EID: 2942527107     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/420932     Document Type: Review

References (23)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998; 338:853-60.
2. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
3. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 14 July 2003. http://aidsinfo.nih.gov/guidelines/adult/archive/AA_071403.html.
4. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44:2093-9.
5. Atazanavir [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2002.
6. Taburet AM, Piketty C, Gerard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a sub-study of puzzle 2-ANRS 107 trial [abstract 537]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:241.
7. O'Mara E, Agarwala S, Randall D, Geraldes M, Stoltz R, Mummaneni V. Steady-state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) in healthy subjects [abstract 444-W]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:220.
8. Agarwala S, Russo R, Mummaneni V, Randall D, Geraldes M, O'Mara E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects [abstract H-1716]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:274.
9. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. Aids 2003; 17:2603-14.
10. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, Group A-CT. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32:18-29.
11. Squires K, Thiry A, Giordano M. Atazanavir (ATV) q. day and efavirenz (EFV) q. day with fixed dose ZDV and 3TC comparison of anti-viral efficacy and safety through week 24 [abstract H-1076]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:267.
12. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-73.
13. DeJesus E, Grinsztejn B, Rodriguez C, et al. Efficacy and safety of atazanavir with ritonavir or saquinavir vs. lopinavir/ritonavir (LPV/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS AI424-045 [abstract 547]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:261.
14. Gong YF, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44:2319-26.
15. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir resistance mutation in treatment naïve HIV-1 patients receiving atazanavir-containing regimens. J Infect Dis 2004; 189:1802-10.
16. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229-34.
17. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS 2003; 17:1258-61.
18. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47:1324-33.
19. Murphy R, Pokrovsky V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008/044 [abstract 555]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:254.
20. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10.
21. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
22. Tackett D, Child M, Agarwala S, et al. Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects [abstract 543]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:249.
23. Mummaneni V, Randall D, Chabuel D, Geraldes M, O'Mara E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects [abstract H-1717]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:275.